Cargando…

A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol

INTRODUCTION: A drawback of gonadotropin-releasing hormone (GnRH) antagonist protocols in in vitro fertilization (IVF) is that they have limited flexibility in cycle programming. This proof of concept study explored the efficacy of a single-dose, long-acting GnRH antagonist IVF protocol. Trial regis...

Descripción completa

Detalles Bibliográficos
Autores principales: Papanikolaou, Evangelos G., Yarali, Hakan, Timotheou, Evi, Grynberg, Michael, Zafeiratis, Odysseas, Tournaye, Herman, Najdecki, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839166/
https://www.ncbi.nlm.nih.gov/pubmed/29545772
http://dx.doi.org/10.3389/fendo.2018.00025
_version_ 1783304367951052800
author Papanikolaou, Evangelos G.
Yarali, Hakan
Timotheou, Evi
Grynberg, Michael
Zafeiratis, Odysseas
Tournaye, Herman
Najdecki, Robert
author_facet Papanikolaou, Evangelos G.
Yarali, Hakan
Timotheou, Evi
Grynberg, Michael
Zafeiratis, Odysseas
Tournaye, Herman
Najdecki, Robert
author_sort Papanikolaou, Evangelos G.
collection PubMed
description INTRODUCTION: A drawback of gonadotropin-releasing hormone (GnRH) antagonist protocols in in vitro fertilization (IVF) is that they have limited flexibility in cycle programming. This proof of concept study explored the efficacy of a single-dose, long-acting GnRH antagonist IVF protocol. Trial registration number is NCT03240159, retrospectively registered on March 08, 2017. MATERIALS AND METHODS: The efficacy of a single-dose long-acting antagonist, degarelix, was explored initially in healthy donors and subsequently in infertile patients. In the first part, five healthy oocyte donors underwent ovarian stimulation with this new protocol: in the late luteal phase, at day 24, a bolus injection of degarelix was administered subcutaneously to control the LH surge in the follicular phase. Ovarian stimulation with gonadotropins was initiated subsequently from day 7 to day 10. End points were first to inhibit the LH surge later in the follicular phase and, second, to retrieve mature oocytes for IVF. In the second part, five infertile women received the same bolus injection of degarelix administered during the luteal phase at day 24. Different gonadotropin starting days (day 2 through day 8) were tested in order to observe possible differences in ovarian stimulation. In these infertile patients, fresh embryo transfers were performed to assess the pregnancy efficacy of this protocol on pregnancy outcomes and to address any possible negative effects on endometrium receptivity. RESULTS: In the first part of the study, all donors were effectively downregulated with a single luteal dose of 0.5 ml of degarelix for up to 22 days until the final oocyte maturation triggering day. Mature oocytes were retrieved after 36 h from all patients and all produced 2–7 blastocysts. In the second part, all five infertile patients achieved sufficient LH downregulation and completed ovarian stimulation without any LH surge. All patients (except one with freeze all strategy) had blastocysts transferred and pregnancy occurred in three out of five women. CONCLUSION: A single dose of the long-acting antagonist degarelix during the luteal phase appears to be effective in downregulating hypophysis during ovarian stimulation. This represents a possible new protocol for IVF, which should be further elucidated in RCTs.
format Online
Article
Text
id pubmed-5839166
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58391662018-03-15 A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol Papanikolaou, Evangelos G. Yarali, Hakan Timotheou, Evi Grynberg, Michael Zafeiratis, Odysseas Tournaye, Herman Najdecki, Robert Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: A drawback of gonadotropin-releasing hormone (GnRH) antagonist protocols in in vitro fertilization (IVF) is that they have limited flexibility in cycle programming. This proof of concept study explored the efficacy of a single-dose, long-acting GnRH antagonist IVF protocol. Trial registration number is NCT03240159, retrospectively registered on March 08, 2017. MATERIALS AND METHODS: The efficacy of a single-dose long-acting antagonist, degarelix, was explored initially in healthy donors and subsequently in infertile patients. In the first part, five healthy oocyte donors underwent ovarian stimulation with this new protocol: in the late luteal phase, at day 24, a bolus injection of degarelix was administered subcutaneously to control the LH surge in the follicular phase. Ovarian stimulation with gonadotropins was initiated subsequently from day 7 to day 10. End points were first to inhibit the LH surge later in the follicular phase and, second, to retrieve mature oocytes for IVF. In the second part, five infertile women received the same bolus injection of degarelix administered during the luteal phase at day 24. Different gonadotropin starting days (day 2 through day 8) were tested in order to observe possible differences in ovarian stimulation. In these infertile patients, fresh embryo transfers were performed to assess the pregnancy efficacy of this protocol on pregnancy outcomes and to address any possible negative effects on endometrium receptivity. RESULTS: In the first part of the study, all donors were effectively downregulated with a single luteal dose of 0.5 ml of degarelix for up to 22 days until the final oocyte maturation triggering day. Mature oocytes were retrieved after 36 h from all patients and all produced 2–7 blastocysts. In the second part, all five infertile patients achieved sufficient LH downregulation and completed ovarian stimulation without any LH surge. All patients (except one with freeze all strategy) had blastocysts transferred and pregnancy occurred in three out of five women. CONCLUSION: A single dose of the long-acting antagonist degarelix during the luteal phase appears to be effective in downregulating hypophysis during ovarian stimulation. This represents a possible new protocol for IVF, which should be further elucidated in RCTs. Frontiers Media S.A. 2018-03-01 /pmc/articles/PMC5839166/ /pubmed/29545772 http://dx.doi.org/10.3389/fendo.2018.00025 Text en Copyright © 2018 Papanikolaou, Yarali, Timotheou, Grynberg, Zafeiratis, Tournaye and Najdecki. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Papanikolaou, Evangelos G.
Yarali, Hakan
Timotheou, Evi
Grynberg, Michael
Zafeiratis, Odysseas
Tournaye, Herman
Najdecki, Robert
A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title_full A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title_fullStr A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title_full_unstemmed A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title_short A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol
title_sort proof-of-concept clinical trial of a single luteal use of long-acting gonadotropin-releasing hormone antagonist degarelix in controlled ovarian stimulation for in vitro fertilization: long antagonist protocol
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839166/
https://www.ncbi.nlm.nih.gov/pubmed/29545772
http://dx.doi.org/10.3389/fendo.2018.00025
work_keys_str_mv AT papanikolaouevangelosg aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT yaralihakan aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT timotheouevi aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT grynbergmichael aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT zafeiratisodysseas aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT tournayeherman aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT najdeckirobert aproofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT papanikolaouevangelosg proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT yaralihakan proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT timotheouevi proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT grynbergmichael proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT zafeiratisodysseas proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT tournayeherman proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol
AT najdeckirobert proofofconceptclinicaltrialofasinglelutealuseoflongactinggonadotropinreleasinghormoneantagonistdegarelixincontrolledovarianstimulationforinvitrofertilizationlongantagonistprotocol